降糖药物与腹主动脉瘤生长及临床结局的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项研究(15个队列,150630名参与者),评估不同降糖药与腹主动脉瘤(AAA)生长及相关事件的关联。结果显示二甲双胍与磺脲类分别与较慢的AAA生长及较低AAA相关事件风险相关,但多数为观察性研究且存在中度偏倚风险,需谨慎解读。
要点
- 二甲双胍与AAA生长减慢(MD -0.65 mm/年)及AAA相关事件减少(OR 0.63)相关。
- 磺脲类与AAA生长减慢(MD -0.35 mm/年)及AAA相关事件减少(OR 0.63)相关。
- DPP-4抑制剂与AAA生长的关联无统计学显著性;二甲双胍与术后死亡率无显著关联。
核心结论
- 二甲双胍和磺脲类与腹主动脉瘤进展减缓相关,但潜在混杂因素要求谨慎解读。
- 其他降糖药物治疗的证据仍然有限,需要随机试验评估药物特异性关联和分层患者群体的结局。
研究设计与样本
- 遵循PRISMA 2020的系统综述与荟萃分析(PROSPERO CRD420251115799),检索MEDLINE、Embase和CENTRAL至2026年1月。
- 纳入13项研究(15个不同队列,150630名参与者),评估降糖药与不使用感兴趣药物的比较,报告AAA生长和/或AAA相关事件。
- 使用ROBINS-I和RoB 2评估非随机研究和随机试验的偏倚风险,采用逆方差随机效应模型计算合并估计值(MD、OR、HR)。
主要发现
- 二甲双胍与较慢的AAA生长相关(MD -0.65 mm/年;95%CI -0.97至-0.33)和较低的AAA相关事件(OR 0.63;95%CI 0.41-0.95)。
- 磺脲类减少AAA生长(MD -0.35 mm/年;95%CI -0.52至-0.18)和AAA相关事件(OR 0.63;95%CI 0.52-0.77)。
- 二肽基肽酶-4抑制剂与AAA生长的关联无统计学显著性(MD -0.32 mm/年;95%CI -0.71至0.08)。
- 二甲双胍与术后死亡率无显著关联(HR 0.86;95%CI 0.65-1.13)。
- 大多数研究为观察性研究,存在中度偏倚风险,限制了因果推断。
临床怎么用
- 对于合并腹主动脉瘤的糖尿病患者,二甲双胍或磺脲类治疗可能与AAA进展减缓及事件减少相关,但需结合个体情况谨慎评估。
- 不应仅基于本观察性证据改变降糖药物选择以预防AAA进展,需等待随机试验证据。
局限性
- 大多数纳入研究为观察性研究,存在中度偏倚风险,限制了因果推断。
- 潜在混杂因素可能导致效应估计偏倚,需谨慎解读。
- 其他降糖药物治疗的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This review aimed to evaluate the association between different antidiabetic agents, abdominal aortic aneurysm (AAA) growth, and related events. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PROSPERO CRD420251115799), MEDLINE, Embase, and CENTRAL were searched through January 2026. Eligible studies evaluated antidiabetic drugs compared with not using the medication of interest and reported AAA growth and/or AAA-related events. The risk of bias was assessed using Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) and RoB 2 for nonrandomized and randomized trials, respectively. Pooled estimates (mean difference [MD], odds ratio [OR], and hazard ratio [HR]) were calculated using inverse variance random-effects models. RESULTS: Thirteen studies (15 distinct cohorts; 150,630 participants) were included. Metformin was associated with slower AAA growth (MD, -0.65 mm/year; 95% confidence interval [CI], -0.97 to -0.33) and lower AAA-related events (OR, 0.63; 95% CI, 0.41-0.95). Moreover, sulfonylureas reduced AAA growth (MD, -0.35 mm/year; 95% CI, -0.52 to -0.18) and AAA-related events (OR, 0.63; 95% CI, 0.52-0.77). Findings for dipeptidyl peptidase-4 inhibitors were not statistically significant in relation to AAA growth (MD, -0.32 mm/year; 95% CI, -0.71 to 0.08). Metformin was not significantly associated with postoperative mortality (HR, 0.86; 95% CI, 0.65-1.13). Most studies were observational, with a moderate risk of bias, which limited causal inference. CONCLUSIONS: Metformin and sulfonylureas were associated with reduced AAA progression, although potential confounding necessitates cautious interpretation. Evidence for other glucose-lowering therapies remains limited. Randomized trials are required to evaluate drug-specific associations and outcomes across stratified patient groups.
引用
- Park Y, Kang S, Lee HW, et al. Associations of antidiabetic medications with abdominal aortic aneurysm growth and clinical outcomes: A systematic review and meta-analysis. J Vasc Surg. 2026. PMID: 41967728. doi:10.1016/j.jvs.2026.03.617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。